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A B S T R A C T   
Background: This study represents a prospective, multicenter, open-label study to assess the safety, performance, 
and outcomes of poly-4-hydroxybutyrate (P4HB, Phasix™) mesh for primary ventral, primary incisional, or 
multiply-recurrent hernia in subjects at risk for complications. This study reports 3-year clinical outcomes. 
Materials and methods: P4HB mesh was implanted in 121 patients via retrorectus or onlay technique. Physical 
exam and/or quality of life surveys were completed at 1, 3, 6,12, 18, 24, and 36 months, with 5-year (60-month) 
follow-up ongoing. 
Results: A total of n = 121 patients were implanted with P4HB mesh (n = 75 (62%) female) with a mean age of 
54.7 ± 12.0 years and mean BMI of 32.2 ± 4.5 kg/m2 (±standard deviation). Comorbidities included: obesity 
(78.5%), active smokers (23.1%), COPD (28.1%), diabetes mellitus (33.1%), immunosuppression (8.3%), cor-
onary artery disease (21.5%), chronic corticosteroid use (5.0%), hypo-albuminemia (2.5%), advanced age 
(5.0%), and renal insufficiency (0.8%). Hernias were repaired via retrorectus (n = 45, 37.2% with myofascial 
release (MR) or n = 43, 35.5% without MR), onlay (n = 8, 6.6% with MR or n = 24, 19.8% without MR), or not 
reported (n = 1, 0.8%). 82 patients (67.8%) completed 36-month follow-up. 17 patients (17.9% ± 0.4%) 
experienced hernia recurrence at 3 years, with n = 9 in the retrorectus group and n = 8 in the onlay group. SSI (n 
= 11) occurred in 9.3% ± 0.03% of patients. 
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Conclusions: Long-term outcomes following ventral hernia repair with P4HB mesh demonstrate low recurrence 
rates at 3-year (36-month) postoperative time frame with no patients developing late mesh complications or 
requiring mesh removal. 5-year (60-month) follow-up is ongoing.   
1. Introduction 
Ventral hernia repair remains one of the most common and chal-
lenging general surgical procedures due to variations in surgical tech-
nique and patient characteristics/comorbidities. The selection of a 
biomaterial to repair the abdominal wall contributes to the complexity 
of the repair, with over 150 devices marketed for this application [1]. 
Historically, permanent synthetic materials were utilized, followed by 
biological tissue-derived materials, and most recently, absorbable ma-
terials such as polyglycolide, polylactide, trimethylene carbonate, and 
poly-4-hydroxybutyrate (P4HB) [2–4]. 
P4HB has received regulatory clearance for use in sutures, as well as 
in medical devices for hernia repair, orthopedic applications, and plas-
tic/reconstructive surgery [5]. P4HB mesh has been used in several 
retrospective and prospective clinical studies for hernia repair with 
medium (18–24 months) to long-term (36+ months) outcomes evalu-
ated [6–10]. P4HB offers a long-term resorption profile of 12–18 
months, providing mechanical support of the defect to prevent early 
hernia recurrence [11,12]. It is unknown how frequently this particular 
device is utilized compared to other similar devices, but some surgeons 
estimate that resorbable hernia repair materials are currently utilized in 
approximately 5% of hernia repair cases (personal communication). 
Resorbable materials such as P4HB have also been utilized for incisional 
hernia prophylaxis [13]. 
P4HB mesh has also been characterized in several preclinical [11,12, 
14] studies. In a 52-week porcine study, P4HB repairs demonstrated a 
consistent strength profile, with mesh-repair strengths significantly 
greater than the native abdominal wall over time, despite significant 
resorption of the P4HB [11]. In a porcine study by Martin et al., P4HB 
fibers exhibited significant decrease in fiber diameter and molecular 
weight, indicating bulk degradation of the polymer throughout the 72 
week study [12]. P4HB fibers displayed evidence of degradation at 48 
weeks, and only small fragments were visible at 72 weeks. However, 
mechanical testing revealed similar strengths between P4HB 
mesh-repaired sites and native porcine abdominal wall at 72 weeks. The 
data from these preclinical studies suggest that P4HB mesh contributes 
to the strength of the porcine abdominal wall for approximately 1 year 
after implantation and contributes negligible strength at 18 months. 
2. Methods 
2.1. Study design 
This study represents a prospective, multicenter, open-label study to 
assess safety, performance, and outcomes of P4HB mesh (Phasix™ Mesh, 
C.R. Bard, Inc., Warwick, RI) for primary ventral or incisional or 
multiply-recurrent hernia repair in a cohort at risk for complications. 
This study has been registered with ClinicalTrials.gov (ClinicalTrials. 
gov/NCT01961687). The primary aim of this study is to evaluate 36- 
month outcomes among patients undergoing hernia repair with P4HB 
mesh. The 36-month outcomes reported here are well beyond the 18–24 
month timeframe reported in the peer-reviewed literature for similar 
resorbable mesh products [15–17], making this study particularly 
unique and relevant to hernia surgeons. This study provides important 
insight into the long-term performance of P4HB mesh at a time point in 
which the mesh itself is no longer contributing to the mechanical 
strength of the repair. At 36 months postimplantation, all of the repair 
strength is dependent upon the strength of the native abdominal wall in 
combination with the host tissue that has been regenerated at the repair 
site. 
Methods were previously described and are repeated here for clarity 
[8]. Subjects were considered at risk for complications with one or more 
of the following comorbidities: body mass index (BMI) between 30 and 
40 kg/m2 (inclusive), active smokers, chronic obstructive pulmonary 
disease (COPD), diabetes mellitus, immunosuppression, coronary artery 
disease, chronic corticosteroid use (>6 months systemic use), 
hypo-albuminemia (pre-operative serum albumin <3.4 g/dL), advanced 
age (≥75 years), or renal insufficiency (serum creatinine concentration 
≥ 2.5 mg/dL). Subjects, investigators, and surgeons were not blinded to 
study treatment. The study was designed to treat 120 subjects at 16 U S. 
sites. The protocol was approved by the Institutional Review Board (IRB) 
at each institution, and all subjects provided informed consent prior to 
enrollment. Recruitment occurred through the surgical offices of the 
Investigators based on the eligibility criteria between October 2013 and 
January 2015. 
2.2. Inclusion/exclusion criteria 
Subjects ≥18 years of age, with primary ventral, primary incisional, 
or recurrent incisional hernia (not to exceed 3 recurrences) were eval-
uated for eligibility, including: one or more comorbidities listed above, 
Class I surgical wound (defined by Centers for Disease Control and 
Prevention (CDC)) [18], and 10–350 cm2 hernia defect suitable for 
repair via retrorectus or onlay mesh (with or without myofascial release, 
MR). Exclusion criteria included: four or more previous hernia repairs 
(of the index repair), peritonitis, on or anticipated to be placed on 
chemotherapy during study period, BMI > 40 kg/m2, cirrhosis of the 
liver and/or ascites, American Society of Anesthesiology Class 4 or 5, 
diagnosed human immunodeficiency virus (HIV) infection, life expec-
tancy of less than 2 years at time of enrollment, planned intra-abdominal 
mesh placement or bridged repair, surgical wound designated Class II 
(clean-contaminated), Class III (contaminated) or Class IV (dirt-
y-contaminated) defined by CDC [18] (no device is currently indicated 
for use in contaminated or infected fields), active or latent systemic 
infection, pregnant or plans to become pregnant during study period, 
currently breastfeeding, enrolled in another clinical study within last 30 
days, part of site personnel directly involved with study, known allergy 
to test device or component materials, or any condition that, in the 
opinion of the Investigator, would preclude the use of the study device, 
or preclude the subject from completing the follow-up requirements. 
2.3. Surgical technique 
All subjects were administered antibiotics according to hospital 
protocol and underwent open ventral hernia repair. Intraoperative in-
clusion and exclusion criteria were assessed and documented. Subjects 
meeting intraoperative eligibility criteria received P4HB mesh, over-
lapping the defect by at least 5 cm with 6–12 resorbable sutures at 
approximately 5–6 cm intervals around the periphery. The hernia defect 
was closed by approximating the fascial edges, including additional 
myofascial release, if required. The fascial and subcutaneous layers were 
closed with sutures, and the skin was closed with staples and/or sutures. 
Operative details including hernia defect size, mesh size, mesh position, 
repair technique, use of myofascial release, suture type, number of su-
tures to secure mesh, and procedural time were collected. Investigators 
were selected based upon experience with hernia repair techniques. No 
specific training was required for participation due to the similarity in 
technique required for P4HB mesh relative to other meshes. Post-
operative care was performed consistent with surgeon practice at each 
site. 
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2.4. Data Collection 
Postoperative patient visits were scheduled at 1, 3, 6,12, 18, 24, 36, 
and 60 months, and a telephone interview was conducted at 30 months. 
Medical history, demographic information, and all current prescription 
and over the counter (OTC) pain medications were recorded. The Pain 
Visual Analogue Scale (VAS) and quality of life assessments: Carolinas 
Comfort Scale® (CCS) and 12-Item Short Form Health Survey® (SF-12) 
were completed preoperatively and at scheduled intervals, along with 
physical examination to assess hernia recurrence, surgical complica-
tions, and adverse events. 
2.5. Study endpoints 
Primary endpoints included: hernia recurrence and surgical site in-
fections (SSI). Hernia recurrence was assessed by physical examination 
at each study visit. A recurrent hernia was defined as any hernia iden-
tified or confirmed by the investigator, during any study follow-up visit, 
within 7 cm of the repair. Hernia recurrence identified via incidental 
magnetic resonance imaging (MRI) or computed tomography (CT) scan 
were evaluated by the operating surgeon for clinical significance and 
confirmation. 
SSI was assessed by physical examination with confirmation by gram 
stain and culture. Superficial and deep SSI were classified according to 
CDC guidelines [19]. SSI may occur due to contamination during the 
surgical procedure, factors related to surgical technique (i.e. tissue 
plane, component separation, inadvertent enterotomy, etc.) or even 
patient comorbidities (i.e. obesity, smoking, diabetes, etc.) [20]. The 
CDC criteria indicate that SSIs are typically diagnosed within the first 
30–90 days [18]. However, the peer-reviewed literature has docu-
mented cases of SSI several years after implantation [20,21]. Thus, the 
current study was designed to capture SSI out to 60 months, with the 
36-month outcomes reported currently. Device-related complications 
and reoperations were also recorded. 
2.6. Analysis population 
GraphPad Prism 6.01 statistical software was utilized to generate 
frequency counts and percentages (categorical variables) and mean ±
standard deviation (continuous variables). The original Statistical 
Analysis Plan indicated that primary endpoints would be expressed 
relative to the modified Intent to Treat (mITT) population and Kaplan- 
Meier analysis. The Intent-to-treat (ITT) population consists of all 
enrolled subjects who signed the Informed Consent Form. The modified 
ITT (mITT) population consists of subjects in the ITT population in 
whom Phasix™ Mesh was implanted. Due to the extension of the orig-
inal study beyond the originally planned 2 years, a higher degree of 
patient loss to follow up occurred than initially planned. Thus, the pri-
mary endpoints are expressed using Kaplan-Meier estimation. Other 
outcome measures utilized the mITT. This work complies with the 
(STROCC) criteria [22]. 
3. Results 
3.1. Subject demographics 
As shown in Tables 1 and 2, a total of n = 121 patients were 
implanted with P4HB mesh (n = 75 (62%) female) an of 54.7 ± 12.0 
years old and BMI of 32.2 ± 4.5 kg/m2 (mean ± standard deviation). The 
majority were white (n = 116, 95.9%) and non-Hispanic/Latino 
ethnicity (n = 113, 94.3%). Comorbidities included (Table 3): obesity 
(78.5%), active smokers (23.1%), COPD (28.1%), diabetes mellitus 
(33.1%), immunosuppression (8.3%), coronary artery disease (21.5%), 
chronic corticosteroid use (5.0%), hypo-albuminemia (2.5%), advanced 
age (5.0%), and renal insufficiency (0.8%).Slightly greater than one 
third of the study population (34.7%) had a single comorbidity, while 
the remainder of the population presented with multiple comorbidities 
(Table 3). 
3.2. Preoperative data 
Hernia types (Table 2) included primary ventral hernia (n = 17, 
14.0%), primary incisional hernia (n = 54, 44.6%), recurrent ventral 
hernia (n = 15, 12.4%), and recurrent incisional hernia (n = 35, 28.9%). 
Table 1 
Flow of participants.  




Met the initial screening criteria (ITT) 139 
Modified intent to treat population (mITT) 121 
Met the intraoperative inclusion/exclusion criteria 117 
Per protocol population (PP) 110 
Withdrew from study 55 
Missing 11 
Lost to Follow-Up after documented 3 attempts to contact 21 
Subject withdrew because of an adverse event related to the study device or 
procedure 
4 
Subject no longer wishes to participate for non-treatment related reasons 5 
Subject moved to an area without an active study site 1 
Subject unable to meet follow-up requirements due to a non-study related 
condition 
1 
Sponsor’s Decision 1 
Death 7 
Other 4 
Completed study 66  
Table 2 
Preoperative data: subject demographics and hernia diagnosis.  
Subjects enrolled n = 121 
Subjects with 36 months follow-up n = 82 (67.8%) 
Sex n = 46 (38%) male 
n = 75 (62%) female 
Age (years) 54.7 ± 12.0 
Body mass index (kg/m2) 32.2 ± 4.5 
Diagnosis Primary ventral: 14.0% 
Primary incisional: 44.6% 
Recurrent ventral: 12.4% 
Recurrent incisional: 28.9%  
Table 3 
Incidence of comorbid conditions in the study population.  
Number of High Risk Criteria Number of Subjects n (%) 
1 42 (34.7%) 
2 45 (37.2%) 
3 24 (19.8%) 
4 6 (5.0%) 
5 3 (2.5%) 
6 1 (0.8%) 
Comorbid Conditions Percentage of Subjects (%) 
BMI (30–40 kg/m2) 78.5 
Hypertension 59.5 




Active smoker 23.1 
Immunosuppression 8.3 
Chronic corticosteroid use 5.0 
Advanced age 5.0 
Hypo-albuminemia 2.5 
Renal insufficiency 0.8  
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The majority of the hernias were located at the midline (n = 102, 
84.3%), and less commonly, suprapubic (n = 5, 4.1%), subxiphoid (n =
3, 2.5%), or not reported (n = 11, 9.1%). 
3.3. Operative characteristics 
Operative characteristics are shown in Table 4. Hernia defects di-
mensions included, length: 14.7 ± 5.6 cm, width: 8.6 ± 3.4 cm, and 
area:115.7 ± 80.6 cm2 (mean ± standard deviation) and were repaired 
with P4HB mesh measuring 459.38 ± 172.3 cm2 (mean ± standard 
deviation). Hernias were repaired via retrorectus technique with MR (n 
= 45, 37.2%), retrorectus without MR (n = 43, 35.5%), onlay without 
MR (n = 24, 19.8%), onlay with MR (n = 8, 6.6%), or not reported (n =
1, 0.8%). Surgical procedure time was 2.8 ± 1.4 h (mean ± standard 
deviation) with at least one drain placed in the majority of patients (n =
107, 88.4%). 
3.4. Postoperative outcomes 
Visual Analog Scores for pain decreased from a score of 3.55 to 0.7 
(preoperatively vs. 36 months, Fig. 1). Patients averaged 5.3 ± 5.3 days 
(mean ± standard deviation) in the hospital (Table 5), with n = 13 
(10.7%) requiring negative pressure wound therapy. Eighty-two pa-
tients (67.8%) completed 36-month follow-up, while thirty-nine pa-
tients were lost to follow-up despite phone calls, electronic 
communication, and mail correspondence. 17 patients experienced a 
hernia recurrence at 3 years (17.9% ± 0.4%), with n = 9 in the retro-
rectus group (12.6% ± 3.9%) and n = 8 in the onlay group (33.2% ±
10.7%). SSI (n = 11, 9.3% ± 0.03%) and seroma requiring intervention 
(n = 8, 6.6%) were low. The time to hernia recurrence and SSI are shown 
in Fig. 2. All SSIs occurred within the first six weeks postimplantation, 
and there were no delayed wound infections. Hernia-related complica-
tions were graded according to the Clavien-Dindo classification in 
Table 6 [23]. 
4. Discussion 
The literature has reported short- and intermediate-term outcomes 
data associated with hernia repair materials [16,17,24]. The current 
study was uniquely designed to assess outcomes along the continuum 
from early (1–12 months) to intermediate (18–24 months) and 
long-term (36–60 months) in subjects at risk for complications. The 
early and intermediate data associated have been published previously 
[8,9]. The current results provide insight into the outcomes at 36 
months, with 60-month follow-up ongoing. Studies by Luijendijk and 
Berger have demonstrated improved outcomes for mesh-based hernia 
repairs relative to suture-based repairs, making mesh-based repairs the 
current standard of care [25,26]. While the majority of synthetic meshes 
result in appropriate clinical outcomes, permanent hernia mesh has been 
increasingly scrutinized due to long-term risk of complications such as 
bowel obstruction, enterocutaneous fistula, infection, seroma, hema-
toma, abscess, or pain [27,28]. The potential impact of a permanent 
synthetic mesh over the course of a lifetime has not been elucidated. An 
understanding of outcomes associated with absorbable mesh provides a 
useful framework for patient discussions. 
Several clinical studies of P4HB mesh have been reported, primarily 
at 18-months [7–9]. In two studies, P4HB mesh was utilized in onlay or 
retrorectus position, with or without myofascial release (MR). Hernia 
recurrence rates and surgical site occurrences (SSO) requiring inter-
vention, including surgical site infection (SSI), seroma, wound dehis-
cence, skin necrosis, hematoma, and fistula were reported. In the 
Plymale study, 31 subjects underwent VIHR with P4HB mesh. At a 
median follow-up of 414 days (~13.8 months), 0% hernia recurrence 
and 19% SSO (12.9% seroma, 3.2% abdominal necrosis, and 3.2% 
wound dehiscence) were reported [9]. In the 18-month reporting of the 
current trial, P4HB mesh was utilized to perform VIHR in 121 subjects 
[8]. Consistent with clinical trials with similar follow-up, outcomes were 
favorable, including: 9% hernia recurrence, 9% SSI, and 6% seroma. In 
the Levy study, P4HB mesh was utilized in a highly morbid study 
Table 4 
Operative data: hernia defect, procedure time, and surgical approach (MR: 
myofascial release).  
Defect (cm2), mean ± SD 115.7 ± 80.6 
Mesh (cm2), mean ± SD 459.38 ± 172.3 
Surgical procedure time (hrs), mean ± SD 2.8 ± 1.4 
Surgical approach  
Retrorectus without MR, n (%) 43 (35.5%) 
Retrorectus with MR, n (%) 45 (37.2%) 
Onlay without MR, n (%) 24 (19.8%) 
Onlay with MR, n (%) 8 (6.6%) 
Other, n (%) 1 (0.8%)  
Fig. 1. Pain Visual Analogue Scale (VAS) results depicted over time.  
Table 5 
Postoperative data- 3 Year Follow-Up: Primary and representative secondary 
outcomes.  
Primary Endpoints Hernia recurrence 17.9 ± 0.4% (n = 17) 
Surgical site infection 9.3 ± 0.03% (n = 11)  
Secondary Outcomes Seroma requiring intervention 6.6% (n = 8) 
Rate of reoperation 11.6% (n = 14) 
Device-related adverse events 15.7% (n = 19)  
Fig. 2. Kaplan-Meier curves for Hernia Recurrence and Surgical Site Infec-
tion (SSI). 
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population of n = 105 patients undergoing component separation with 
onlay P4HB [7]. Eighteen patients (n = 18, 17%) experienced a hernia 
recurrence at a mean of 18 months follow-up (range: 2–36 months). Low 
rates of infection (n = 5, 5%) and seroma (n = 6, 6%) were also reported. 
To date, long-term clinical outcomes associated with P4HB mesh have 
not been reported beyond these 18–24 month studies, possibly due to 
the high costs associated with conducting a long-term clinical trial. 
Thus, the current study extends the previously published study and re-
ports the 3-year postoperative outcomes associated with P4HB mesh in 
the same prospective, multicenter trial in subjects at risk of post-
operative complications. This study provides important insight into the 
long-term performance of P4HB mesh at a time point in which the mesh 
itself is no longer contributing to the mechanical strength of the repair. 
At 36 months postimplantation, all of the repair strength is dependent 
upon the strength of the native abdominal wall in combination with the 
host tissue that has been regenerated at the repair site. 
The results of the current study revealed 17.9% ± 0.4% hernia 
recurrence, 6.6% seroma, and 9.3% ± 0.03% SSI at 36 months. Impor-
tantly, all SSIs occurred within the first six weeks postimplantation, and 
there were no delayed wound infections. These results compare well 
with several other published studies. In a prospective, randomized study 
comparing mesh repair to suture repair without mesh, Luijendijk et al. 
reported 24% recurrence at 3 years for mesh repairs compared to 43% 
recurrence for suture repairs [26]. In a prospective, Danish, nationwide 
hernia database study, Helgstrand et al. reported outcomes after elective 
incisional hernia repair via onlay, retrorectus, or intraperitoneal mesh 
placement [29]. With a long-term median follow-up of 48 months, 
Helgstrand et al. observed an 18.3% overall hernia recurrence rate and 
9.5% reoperation rate comparable to the current study (17.9% and 
11.6%, respectively). A 21% recurrence rate was reported for open re-
pairs, which is greater than the current study. Onlay repairs had a 
hazard ratio of 1.7, consistent with the current study. In a prospective, 
randomized controlled trial, Sevinc et al. evaluated outcomes associated 
with onlay versus retrorectus mesh placement for incisional hernia 
repair, with 50 subjects in each group [30]. At a median follow-up of 
37.1 months, Sevinc et al. observed a 4% incidence of SSI and an 8% 
incidence of seroma, which compare well to the current study at 9.3% ±
0.03% and 6.6%, respectively. However, the subjects in the Sevinc et al. 
study had a BMI of 25.9 ± 3.5 kg/m2 and hernia defect of 73.4 ± 66.3 
cm2, while patients in the current study had a BMI of 32.2 ± 4.5 kg/m2 
and hernia defect of 115.7 ± 80.6 cm2. 
When the results of the current study were separated into onlay 
versus retrorectus repairs, the recurrence rates were 2.5 times higher in 
the onlay group compared to the retrorectus group, with an overall 
recurrence rate of 17.9% ± 0.4%. Several studies have demonstrated 
similar ratios of 2–3 times greater onlay recurrence rates compared to 
retrorectus recurrence rates, comparable to the current study [30–35]. 
In a systematic review of the literature, Sosin et al. compared outcomes 
and complications associated with onlay, retrorectus, interposition, and 
underlay ventral hernia repair techniques. At a mean follow-up of 37.5 
months, they reported an overall mean recurrence rate of 8.3% (12.9% 
onlay and 5.8% retrorectus, ratio of 2.2). SSI and seroma/hematoma 
were 11.1% and 11.3%, respectively, which compare well with the 
current data. In another systematic review and meta-analysis, Holihan 
et al. evaluated hernia recurrence and SSI associated with open ventral 
hernia repair [33]. With follow-up ranging from 12 to 98 months, 
Holihan et al. reported a significantly higher recurrence rate (16.5% vs. 
7%, OR 0.218) and incidence of SSI (16.9% vs. 3.7%, OR 0.449) for 
onlay repairs compared to retrorectus repairs (2.4 times greater re-
currences for onlay vs. retrorectus). Finally, Levy et al. reported a 
recurrence rate of 17% for onlay P4HB mesh repair with component 
separation in a highly morbid study population in which 91% had one or 
more major comorbidities [7]. 
This study represents a prospective, multicenter trial with long-term 
follow-up rather than a randomized controlled trial. Several other peer- 
reviewed studies have evaluated other resorbable synthetic or biologic 
hernia repair materials such as TIGR® Matrix [15], Gore® Bio-A® [36], 
and Strattice™ [17] in similar single arm studies, albeit with shorter 
follow-up periods. Historically, randomized controlled trials in hernia 
repair have primarily focused on technique rather than biomaterial 
comparisons [25,37,38]. However, head-to-head comparisons of devices 
are commonly addressed in animal studies. Several important 
Table 6 
Hernia-related complications graded according to Clavien-Dindo classification.  
Clavien-Dindo Scores Grade I Grade II Grade IIIa Grade III b Grade IVa Grade IVb Grade V 
Hernia-Related Complications (n) (n) (n) (n) (n) (n) (n)  
Abdominal abscess 0 0 1 1 0 0 0 
Abdominal wall disorder 1 0 0 1 0 0 0 
Abdominal wound dehiscence 17 1 0 0 0 0 0 
Drain complications (erythema, pain) 2 0 0 0 0 0 0 
Ecchymosis 1 0 0 0 0 0 0 
Epidermal necrosis 1 0 0 0 0 0 0 
Erythema (incision site cellulitis, incision site erhthema, erythema) 7 0 0 0 0 0 0 
Eventration (diastasis recti abdominis, hernial eventration) 4 0 0 0 0 0 0 
Hematoma (incision site, intra-abdominal, post-procedural, subcutaneous) 10 1 0 0 0 0 0 
Impaired healing 1 0 0 0 0 0 0 
Implant site ischaemia 2 0 0 0 0 0 0 
Incision site haemorrhage 3 0 0 0 0 0 0 
Incision site oedema 1 0 0 0 0 0 0 
Incision site vesicles 1 0 0 0 0 0 0 
Infusion site urticaria 0 1 0 0 0 0 0 
Necrosis (muscle, skin) 6 0 0 0 0 0 0 
Pain or tenderness (abdominal, incision site, procedural) 49 2 2 0 0 0 0 
Post procedural discharge 3 0 0 0 0 0 0 
Postoperative wound complication 6 0 0 0 0 0 0 
Postoperative wound infection 9 1 1 0 0 0 0 
Seroma 15 0 0 0 0 0 0 
Skin infection 1 0 0 0 0 0 0 
Skin ulcer 1 0 0 0 0 0 0 
Suture related complication 1 0 0 0 0 0 0 
Umbilical hernia 0 0 1 1 0 0 0 
Wound abscess 0 0 1 0 0 0 0 
Wound complication 1 0 0 0 0 0 0 
Wound dehiscence 3 0 0 0 0 0 0  
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limitations of the current study should be acknowledged, including the 
lack a control group and the fact that all of the patients had Class I 
(clean) wounds. As such, the data cannot be directly compared to other 
biomaterials or other wound types. However, the data provide impor-
tant insight into the long-term performance of P4HB mesh at a time 
point in which the mesh itself is no longer contributing to the me-
chanical strength of the repair. At 36 months postimplantation, all of the 
repair strength is dependent upon the strength of the native abdominal 
wall in combination with the host tissue that has been regenerated at the 
repair site. Future prospective randomized trials comparing outcomes to 
other biomaterials are needed to understand outcomes relative to other 
biomaterials. 
5. Conclusion 
Long-term outcomes following VIHR with P4HB mesh demonstrate 
low recurrence rates at the 3-years (36-months). 5-year (60-month) 
follow-up is ongoing. 
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